Rheumatoid Arthritis News

The COVID-19 pandemic resulted in a rapid adoption of telemedicine among rheumatologists and a delaying of advanced treatments for rheumatoid arthritis, according to data published in Rheumatology Advances in Practice.

Inhalable substances associated with occupational settings may act as “important” environmental triggers for developing rheumatoid arthritis, according to data published in the Annals of the Rheumatic Diseases.

In patients with active rheumatoid arthritis despite methotrexate use, adding either a TNF inhibitor or triple therapy with sulfasalazine and hydroxychloroquine improves vascular inflammation, according to data.

Autoimmune disorders were associated with elevated atrial fibrillation risk, particularly in women, according to a study published in EP Europace.

A slew of recent clinical trials and the continued development of new treatments have ensured that the state of rheumatoid arthritis treatment is more advanced than ever before.